Viral Vector Development
& Manufacturing
Accelerate your CGT’s journey from lab to patient.
With increasing companies exploring niches in the CGT sector, the demand for specialised development and manufacturing of viral vectors is surging. The need for highly specific vector expertise is at the core of this scientific shift—as unique as the therapies you develop. There is no universal blueprint; your work deserves a custom-crafted strategy to swiftly and safely bring life-saving therapies to those in need.
Partnering with Us, You Accelerate Your Path to Market
In viral vector development, the journey from concept to clinical application demands a combination of scientific know-how and commercial experience — core expertise in the professionals working at NecstGen. We facilitate your translational journey within a state-of-the-art, GMP-compliant development and manufacturing facility, ensuring your project meets the highest standards.
Our team is adept at crafting meticulously tailored process designs to meet your therapy’s distinct needs. We are well-versed in the nuances of scaling up production to clinically relevant volumes, an essential step to meet increasing demand while maintaining the integrity of your product.
Lentiviruses (LV)
Ideal for stable gene delivery, with a track record of safety and efficacy.
Adeno-associated viruses (AAV)
The vector of choice for targeting various tissues with minimal immune response.
Oncolytic viruses
Harnessing the power of virotherapy to selectively target and destroy cancer cells.
Continuity Though Product Development
Our commitment to scalability spans every trial phase in viral vector manufacturing, ensuring you can access state-of-the-art production capabilities when it matters most. From the crucial early stages of pre-clinical studies or toxicology material production, NecstGen provides robust support in developing and manufacturing viral vectors.
As your therapy progresses, we ensure the seamless transition from one phase to the next, providing reliable and high-quality viral vector supplies from Phase I to Phase III clinical trials.
This continuity is the bedrock of our service, guaranteeing not just consistency in the product but also confidence in the process. It allows our scientific partners to focus on the pivotal task of advancing their therapies through the trial phases toward ultimate regulatory approval and patient application.
Watch Replay
Product Quality For Cell Therapies
Our experts can provide insights and answer your queries to advance your Cell Therapy development. This webinar is designed to help you explore and navigate the complexities of product quality strategies for cell therapies. Still, if you have additional questions, we invite you to ask us your questions.
